XERS Stock Recent News

Xeris Biopharma Holdings Inc (NASDAQ:XERS) posted record revenue growth for the fourth quarter and full-year 2022 and has issued bullish 2023 financial guidance. In the results statement, Paul R.

Xeris Biopharma expects to report record net product revenue for 2022 thanks to strong growth across their portfolio of approved products. Xeris believes they are still on track to hit its goal of cash flow breakeven by the end of 2023.

Xeris Biopharma Holdings (NASDAQ:XERS) Inc revealed that the Food and Drug Administration (FDA) granted its subsidiary Xeris Pharmaceuticals Inc, orphan-drug exclusivity (ODE) for Recorlev (levoketoconazole) for the treatment of adult patients with endogenous Cushing's syndrome, for whom surgery is not an option, or hasn't worked. Endogenous Cushing's syndrome is a rare and potentially fatal endocrine disease caused by chronic elevated cortisol exposure, which is often the result of a benign tumor of the pituitary gland.

Penny stocks fueled by news catalysts this week. The post 5 Hot Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Xeris Biopharma Holdings (NASDAQ:XERS) Inc announced that it will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium (SC injection) as replacement therapy for hypothyroidism. The Chicago-based firm made the decision based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris told investors.

Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.

Xeris Biopharma reported its Q3 earnings with a beat on EPS and revenue. Xeris reported strong growth with record net product revenue rising 17% from the previous quarter. Xeris looks to be on track to hit its goal of cash flow breakeven by the end of 2023.

Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced record third-quarter financial results and subsequently raised its 2022 year-end cash balance guidance. The company reported record net product revenue of $29.6 million, up 17% quarter-over-quarter and 31% year-over-year on a pro forma basis.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Communications Paul Edick - Chairman and CEO Steve Pieper - Chief Financial Officer Conference Call Participants Glen Santangelo - Jefferies David Amsellem - Piper Sandler Oren Livnat - H.C. Wainwright Roanna Ruiz - SVB Securities Operator Good evening or good afternoon.

Xeris Biopharma Holdings (NASDAQ:XERS) Inc revealed the results of the extended evaluation of levoketoconazole, or Recorlev, from the Phase 3 SONICS study published in the European Journal of Endocrinology. The study evaluated longer-term effects of Recorlev on cortisol levels, biomarkers of Cushing's syndrome (CS) comorbidities, clinical signs and symptoms of CS, and quality of life.